Minireviews
Copyright ©2013 Baishideng Publishing Group Co.
World J Pharmacol. Dec 9, 2013; 2(4): 100-106
Published online Dec 9, 2013. doi: 10.5497/wjp.v2.i4.100
Figure 1
Figure 1 Mutated p53 and the mevalonate pathway in tumor progression. Mutated p53 actively promotes cancer progression, particularly in breast cancer. Controlled by the sterol regulatory element-binding proteins (SREBP) mutated p53 disrupts the mammary tissue architecture by up-regulation of the mevalonate pathway[28].